Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Roden

Showing results (71-80 of 684) with videos related to

Pageof 69
Sort By:
Journal of Diabetes and Its Complications|October 30, 2024
Precision diabetology: Where do we stand now?Christian Herder, Manfredi Rizzo, Michael Roden
Hormones (Athens, Greece)|August 1, 2025
Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humansAnna Giannakogeorgou, Michael Roden, Kalliopi Pafili
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?Benjamin Schröder, Sabine Kahl, Michael Roden
Journal of Hepatology|November 19, 2016
Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease"Giulio Marchesini, Michael Roden, Roberto Vettor
American Journal of Physiology. Cell Physiology|May 4, 2022
The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humansAsen Georgiev, Cesare Granata, Michael Roden
Trends in Pharmacological Sciences|August 10, 2011
The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impactEsther Phielix, Julia Szendroedi, Michael Roden
Nature Reviews. Endocrinology|September 14, 2011
The role of mitochondria in insulin resistance and type 2 diabetes mellitusJulia Szendroedi, Esther Phielix, Michael Roden
Molecular Metabolism|March 18, 2014
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanismsAlin Stirban, Thomas Gawlowski, Michael Roden
Seminars in Liver Disease|July 21, 2021
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic SteatohepatitisSabine Kahl, Jennifer Pützer, Michael Roden
Metabolism: Clinical and Experimental|May 23, 2024
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?Maximilian Huttasch, Michael Roden, Sabine Kahl
Pageof 69

Showing results (71-80 of 684) with videos related to

Sort By:
Pageof 69
Journal of Diabetes and Its Complications|October 30, 2024
Precision diabetology: Where do we stand now?Christian Herder, Manfredi Rizzo, Michael Roden
Hormones (Athens, Greece)|August 1, 2025
Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humansAnna Giannakogeorgou, Michael Roden, Kalliopi Pafili
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?Benjamin Schröder, Sabine Kahl, Michael Roden
Journal of Hepatology|November 19, 2016
Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease"Giulio Marchesini, Michael Roden, Roberto Vettor
American Journal of Physiology. Cell Physiology|May 4, 2022
The role of mitochondria in the pathophysiology and treatment of common metabolic diseases in humansAsen Georgiev, Cesare Granata, Michael Roden
Trends in Pharmacological Sciences|August 10, 2011
The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impactEsther Phielix, Julia Szendroedi, Michael Roden
Nature Reviews. Endocrinology|September 14, 2011
The role of mitochondria in insulin resistance and type 2 diabetes mellitusJulia Szendroedi, Esther Phielix, Michael Roden
Molecular Metabolism|March 18, 2014
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanismsAlin Stirban, Thomas Gawlowski, Michael Roden
Seminars in Liver Disease|July 21, 2021
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic SteatohepatitisSabine Kahl, Jennifer Pützer, Michael Roden
Metabolism: Clinical and Experimental|May 23, 2024
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?Maximilian Huttasch, Michael Roden, Sabine Kahl
Pageof 69